Results 131 to 140 of about 669,583 (341)

Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Features of clinically significant portal hypertension (CSPH) in patients with autoimmune hepatitis indicate a substantial risk for decompensation and impaired transplant‐free survival. Non‐invasive risk prediction based on liver stiffness measurement ≥ 15 kPa and/or thrombocytopenia (< 150 G/L) serves as a valuable surrogate to identify patients at ...
Lukas Burghart, Sonja Treiber, David Bauer, Emina Halilbasic, Benedikt S. Hofer, Mattias Mandorfer, Michael Gschwantler, Caroline Schwarz, Michael Trauner, Thomas Reiberger, Albert F. Stättermayer   +10 more
wiley   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Covert hepatic encephalopathy: a neglected topic—a narrative review

Egyptian Liver Journal
Covert hepatic encephalopathy (CHE) is a form of cerebral dysfunction that affects 30–40% of patients with liver cirrhosis as a grave sequel of disease progression. Although being a silent condition, yet; CHE has been reported as seriously predictive for
Mohamed Elbadry, Amin Abdel Baki, Asmaa bakr, Eman A. Elhamrawy, Hayam Abdel-Tawab, Abdelghany Aish, Israa Nooh, Abdulmoneim Adel, Moataz Y. Soliman, Nessren Mohammed, Samy Zaky   +10 more
doaj   +1 more source

Hepatic Telangiectases and Portosystemic Encephalopathy in Osler-Weber-Rendu Disease

, 1968
Dan Michaeli, Isaac Ben‐Bassat, Hylton I. Miller, Victor Deutsch   +3 more
openalex   +1 more source

Research Communication: The Cumulated Spontaneous Portosystemic Shunts (SPSS) Area Decreases After TIPS and Impacts on Prognosis

Alimentary Pharmacology &Therapeutics, EarlyView.
This study shows that both the total SPSS area and the cumulative SPSS diameter decrease significantly and persistently after TIPS placement, whereas the total shunt diameter increases slightly and the total shunt area remains stable. The relative change in SPSS area serves as an independent predictor of mortality. ABSTRACT We evaluated the dynamics of
Marlene Hintersteininger, Theresa Müllner‐Bucsics, Susanna Riegler, Nina Dominik, Georg Kramer, Christian Sebesta, Paul Thöne, Ulrika Asenbaum, Lukas Reider, Maria Schoder, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Lukas Hartl, Katharina Lampichler   +14 more
wiley   +1 more source

A method for serum octanoate in hepatic cirrhosis and hepatic encephalopathy.

, 1977
Joseph L. Rabinowitz, J Staeffen, P Aumonier, P Ballan, Joana Ferrer, R Terme, C. Sériès, Ralph M. Myerson   +7 more
openalex   +1 more source

Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression

Alimentary Pharmacology &Therapeutics, EarlyView.
In‐depth multiomics analyses revealed that the gut microbiota in patients with CPH is dysbiotic. Altered gut microbiota plays an important role in the progression of CPH and affects the host's arginine metabolism to promote arginine biosynthesis. The pro‐inflammatory effects of certain gut bacteria induce iNOS expression, which together act on the ...
Qun Zhang, Jinghua Cui, Yixin Hou, Lining Guo, Hai Li, Guiqin Zhou, Xiaojing Wang, Bingbing Zhu, Ke Shi, Yi Zhang, Yufei Bi, Yanqiu Li, Lina Sun, Ying Feng, Jing Yuan, Xianbo Wang   +15 more
wiley   +1 more source

BRAIN PROTEINS IN HEPATIC ENCEPHALOPATHY

, 1977
Arne Brun, Sigmund Dawiskiba, Bengt Hindfelt, Jan-Edvin Olson   +3 more
openalex   +1 more source

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
Extracellular matrix (ECM) remodelling biomarkers reflect portal hypertension and disease severity in advanced chronic liver disease (ACLD). However, their predictive value for disease progression is largely restricted to compensated ACLD (cACLD). ABSTRACT Background Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is ...
Benedikt Simbrunner, Ida Falk Villesen, Georg Semmler, Lorenz Balcar, Georg Kramer, Joana Almeida Calvão, Benedikt Silvester Hofer, Mathias Jachs, Lukas Hartl, Jurij Maurer, Bernhard Scheiner, Kerstin Zinober, Rodrig Marculescu, Michael Trauner, Morten Karsdal, Thomas Reiberger, Mattias Mandorfer, Diana Julie Leeming   +17 more
wiley   +1 more source